


# **ВИЧ-инфекция и особенности В-клеточного иммунитета**

Оксана Владимировна Айзсилниекс

Врач-инфекционист отдела Эпидемиологии ПСПбГМУ

Старший лаборант кафедры инфекционных болезней и  
эпидемиологии ПСПбГМУ

Старший лаборант кафедры гематологии, трансфузиологии и  
трансплантологии ПСПбГМУ



SHVARZ

## Yegor Voronin

[\[Recent Entries\]](#)[\[Archive\]](#)[\[Friends\]](#)[\[Profile\]](#)Below are the 25 most recent journal entries recorded in the "[Yegor Voronin](#)" journal:[\[<< Previous 25 entries\]](#)

## July 11th, 2019

02:21 pm **Журнал**

Журналу исполнилось 13 лет.

Меня зовут Егор Воронин, хотя последние 19 лет (с тех пор как я приехал в Штаты) я чаще пишу свое имя как Yegor Voronin. Хотя в этом журнале я пишу всегда лишь о том, что лично мне в данный момент интересно, опрос в комментариях к этой записи говорит, что большинство читателей ко мне приходят за постами о науке, в основном о ВИЧ. Я изучал этот вирус (и его родственников) в лаборатории лет 12, а последние 7 лет я работаю в очень маленькой организации Global HIV Vaccine Enterprise, которая поддерживает работу очень большого альянса организаций, работающих над вакциной от ВИЧ.

[\[Link\]](#)

Большинство записей в журнале помечены тэгами, пользуйтесь ими для того, чтобы найти то, что вам интересно. Под катом в этом посте - небольшая выборка из написанного за 13 лет, чтобы вам проще было сориентироваться.


( [Read more...](#) )Tags: [ЖЖ](#)[\(367 comments | Leave a comment\)](#)

## February 17th, 2017

04:42 pm **Олигонуклеотиды как лекарство**

Жена навела на интересную историю. Часто доводится писать об открытиях, которым до клиники еще годы, а тут открытию уже лет десять примерно и буквально месяц-другой назад оно как раз добралось до клиники.

Есть такая очень страшная генетическая болезнь - spinal muscular atrophy (SMA), поражает примерно одного на 10,000 новорожденных.



## Back Issues

### OPENING THE ENVELOPE

The premier gathering of HIV vaccine researchers showcased a healthy dose of progress in understanding HIV's structure and how it can be utilized to engineer better vaccine candidates

By Yegor Voronin and Noah Sather\*

"Three atomic-level structures of HIV envelope were released over the past two years," said Peter Kwong of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID). "At this meeting, I've already seen six new trimer structures, and the meeting is barely half over."

The meeting was the Keystone Symposium on HIV Vaccines, which took place March 22-27 in Banff, Canada, and, for the record, Peter counted a total of 10 new HIV envelope (Env) structures that were unveiled there, reflecting the rapidly accelerating pace of progress in defining the structure of HIV's outer surface protein. This sentiment extended to the whole meeting, as several directions of HIV vaccine research, none of which are completely new, showed spectacular progress in the recent months.

#### Epitope mapping reveals surprises

New structures of Env illuminate how the genetic diversity of HIV results in the diversity of protein structures, which allows the virus to efficiently evade the immune system. They also reveal the conserved motifs that are targeted by antibodies capable of neutralizing a broad swath of HIV isolates (so-called broadly neutralizing antibodies or bNAbs). At Keystone, Pamela Bjorkman from the California Institute of Technology presented data showing that an antibody referred to as 8ANC195 binds to HIV Env in a manner different from all previously identified bNAbs. Although initial analysis showed that 8ANC195 competes with antibodies targeting the CD4 binding site (CD4bs) on Env, crystal structures revealed that it actually binds to a distinct region nearby and that its epitope spans the gp120 and gp41 subunits of Env.

#### TABLE OF CONTENTS

Vol. 19, No. 1, 2015

#### [PrEP Works](#)

#### [The Trimer Transformed](#)

#### [Opening the Envelope](#)

#### [DOWNLOAD THIS ISSUE \[PDF\]](#)

#### FOLLOW US





# The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

The Council of the Global HIV Vaccine Enterprise, Seth Berkley, Kenneth Bertram, Jean-François Delfraissy, Ruxandra Draghia-Akli, Anthony Fauci, Cynthia Hallenbeck, Madame Jeannette Kagame, Peter Kim, Daisy Mafubelu, Malegapuru W Makgoba, Peter Piot, Mark Walport, Mitchell Warren & Tadataka Yamada for Members of the Enterprise, José Esparza, Catherine Hankins, Margaret I Johnston, Yves Lévy & Manuel Romaris for Alternate members, Rafi Ahmed & Alan Bernstein for Ex-officio members

[Affiliations](#) | [Corresponding author](#)

*Nature Medicine* 16, 981–989 (2010) | doi:10.1038/nm0910-981



PDF



Citation



Reprints



Rights & permissions



Article metrics

**Subject terms:** [HIV infections](#) · [Public health](#) · [Vaccines](#)

## - An important moment in HIV vaccine research

An important moment in HIV vaccine research · [The Global HIV Vaccine Enterprise](#) · [The 2010 Plan's two scientific priorities](#) · [Cross-cutting considerations](#) · [Conclusions and next steps](#) · [References](#) ·

[Acknowledgments](#) · [Author information](#)



[AIDS Res Hum Retroviruses](#). 2016 Nov 1; 32(10-11): 944–946.

PMCID: PMC5067853

Published online 2016 Nov 1. doi: [10.1089/aid.2016.0120](https://doi.org/10.1089/aid.2016.0120)


## The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field

[Jeffrey T. Safrit](#),<sup>1</sup> [Georgia D. Tomaras](#),<sup>2</sup> [Tomáš Hanke](#),<sup>3</sup> [Allan C. deCamp](#),<sup>4</sup> and [Yegor Voronin](#)<sup>5</sup>

[Author information](#) ► [Copyright and License information](#) ►

HIV-1 VACCINE DEVELOPMENT is rapidly advancing numerous diverse vaccine candidates based on a variety of hypotheses about what constitutes protective HIV-1 immunity.<sup>1–3</sup> It is common to differentiate vaccine candidates as being antibody-based, T-cell-based, or both, which is a useful classification, but it does not provide enough granularity to capture the multiple hypotheses regarding the contribution of particular immune responses to protection against HIV-1.



We conducted a landscape analysis of the immune responses that are viewed as potentially protective by HIV-1 vaccine researchers ([Fig. 1](#)). We interviewed 10 investigators involved in 12 current phase I/IIa studies and asked them to list the immune responses that they wished to elicit with their vaccine candidate(s) divided into the following three categories:





**FIG. 1.**

Immune landscape of candidates based on the minimal (**A, B**) or the optimal (**C, D**) desired immune responses. (**A, C**) show frequency distribution of immune responses identified as desired for the surveyed vaccine candidates. The numbers represent the number ...

### Minimal landscape



### Optimal landscape





## Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Easterhoff D<sup>1</sup>, Moody MA<sup>1</sup>, Fera D<sup>2</sup>, Cheng H<sup>3</sup>, Ackerman M<sup>3</sup>, Wiehe K<sup>1</sup>, Saunders KO<sup>1</sup>, Pollara J<sup>1</sup>, Vandergrift N<sup>1</sup>, Parks R<sup>1</sup>, Kim J<sup>4</sup>, Michael NL<sup>4</sup>, O'Connell RJ<sup>5</sup>, Excler JL<sup>4,6</sup>, Robb ML<sup>4</sup>, Vasan S<sup>5</sup>, Rerks-Ngarm S<sup>7</sup>, Kaewkungwal J<sup>8</sup>, Pitisuttithum P<sup>9</sup>, Nitayaphan S<sup>9</sup>, Sinangil F<sup>10</sup>, Tartaglia J<sup>11</sup>, Phogat S<sup>11</sup>, Kepler TB<sup>12</sup>, Alam SM<sup>1</sup>, Liao HX<sup>1</sup>, Ferrari G<sup>1</sup>, Seaman MS<sup>13</sup>, Montefiori DC<sup>1</sup>, Tomaras GD<sup>1</sup>, Harrison SC<sup>2</sup>, Haynes BF<sup>1</sup>.

### ⊕ Author information

#### Abstract

The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (**bnAbs**), no plasma bnAb activity was induced. The RV305 ([NCT01435135](#)) HIV-1 clinical trial was a placebo-controlled randomized double-blinded study that assessed the safety and efficacy of vaccine boosting on B cell repertoires. HIV-1-uninfected RV144 vaccine recipients were reimmunized 6-8 years later with AIDSVAX B/E gp120 alone, ALVAC-HIV alone, or a combination of ALVAC-HIV and AIDSVAX B/E gp120 in the RV305 trial. Env-specific post-RV144 and RV305 boost memory B cell VH mutation frequencies increased from 2.9% post-RV144 to 6.7% post-RV305. The vaccine was well tolerated with no adverse events reports. While post-boost plasma did not have bnAb activity, the vaccine boosts expanded a pool of envelope CD4 binding site (bs)-reactive memory B cells with long third heavy chain complementarity determining regions (HCDR3) whose germline precursors and affinity matured B cell clonal lineage members neutralized the HIV-1 CRF01 AE tier 2 (difficult to neutralize) primary isolate, CNE8. Electron microscopy of two of these antibodies bound with near-native gp140 trimers showed that they recognized an open conformation of the Env trimer. Although late boosting of RV144 vaccinees expanded a novel pool of neutralizing B cell clonal lineages, we hypothesize that boosts with stably closed trimers would be necessary to elicit antibodies with greater breadth of tier 2 HIV-1 strains.

**TRIAL REGISTRATION:** ClinicalTrials.gov [NCT01435135](#).

PMID: 28235027 DOI: [10.1371/journal.ppat.1006182](#)

[PubMed - as supplied by publisher] [Free full text](#)

#### Full text links



#### Save items



#### Similar articles

A phase 1/2 comparative vaccin safety and imr [J Acquir Immune

HIV gp120 vaccine - VaxGen: AI AIDSVAX B/B, AIDSVAX B/E, I [

Differential binding of neutralizin neutralizing antibodies to na [Re

**Review** The HIV-1 gp120 V1V2 function and importa [Expert Re

**Review** Lessons from the RV14 HIV-1 vaccine trial and the [Anni

#### Related information

MedGen

## Table 1

### Summary of immunogen design strategies and progress in evaluation

Design strategy	Expected outcome	<i>In vitro</i> evaluation	Animal trials	Human trials	Key ref.
1. Mimicking native trimer: remove non-functional Env from VLP	bNAb	Recognised by NAb but not non-NAb	-	-	[29,31]
2. Mimicking native trimer: soluble SOSIP-modified Env trimer	bNAb	Recognised by bNAb but not non-NAb Resembles Env trimer by electron microscopy	-	-	[39]
3. Stabilised bNAb epitope: epitope-scaffolds	bNAb	Bound to bNAb	Ones tested did not elicit NAb	-	[33,46,47]
4. Stabilised bNAb epitope: targeting germline and driving maturation	bNAb	Potently activated germline and mature VRC01 B cells	-	-	[49]
5. Stabilised bNAb epitope: fragment immunogen	bNAb	Ab induced in rabbits neutralised tier I, II and III viruses	Induced b12 bNAb in rabbits	-	[51]
6. Mosaic immunogens	T cell responses to diverse strains, reduce escape	Processed and expressed by human T cells	Increased breadth and depth of T cell responses Reduced per exposure probability of infection by $\approx$ 90%	-	[67,70-72]
7. Conserved element immunogens	T cell responses to diverse strains, reduce escape/attenuate virus	T cell responses elicited in humans inhibited viruses	Highly immunogenic	High magnitude and breadth of T cell responses in 100% vaccinees	[21,81]
8. Escape-cornering immunogens (computational model)	Reduce escape/attenuate virus	Fitness testing of mutants supported model predictions	-	-	[84,86]
9. Immunogens using CMV vectors	Persistent T cell responses to act early	-	50% monkeys clear SIV infection early Persistent, unusually broad T cell responses	-	[55,91,92]

ref – references; VLP – virus-like particles; bNAb – broadly neutralising antibodies; NAb – neutralising antibodies; SOSIP - disulphide bond between gp120 and gp41 and gp41 trimer stabilising mutation I559P; Env – envelope; CMV – cytomegalovirus; SIV – simian immunodeficiency virus.

WILEY

IMMUNOLOGICAL REVIEWS

[This Article](#)[For Authors](#)[Learn More](#)[Submit](#)[Immunol Rev.](#) 2017 Jan; 275(1): 62–78.

PMCID: PMC5299500

Published online 2017 Jan 30. doi: [10.1111/imr.12504](https://doi.org/10.1111/imr.12504)

## Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies

Persephone Borrow<sup>1</sup> and M. Anthony Moody<sup>2</sup>[Author information](#) ▶ [Copyright and License information](#) ▶

### Summary

[Go to:](#) 

Induction of broadly neutralizing antibodies (bnAbs) capable of inhibiting infection with diverse variants of human immunodeficiency virus type 1 (HIV-1) is a key, as-yet-unachieved goal of prophylactic HIV-1 vaccine strategies. However, some HIV-infected individuals develop bnAbs after approximately 2–4 years of infection, enabling analysis of features of these antibodies and the immunological environment that enables their induction. Distinct subsets of CD4<sup>+</sup> T cells play opposing roles in the regulation of humoral responses: T follicular helper (Tfh) cells support germinal center formation and provide help for affinity maturation and the development of memory B cells and plasma cells, while regulatory CD4<sup>+</sup> (Treg) cells including T follicular regulatory (Tfr) cells inhibit the germinal center reaction to limit autoantibody production. BnAbs exhibit high somatic mutation frequencies, long third heavy-chain complementarity determining regions, and/or autoreactivity, suggesting that bnAb generation is likely to be highly dependent on the activity of CD4<sup>+</sup> Tfh cells, and may be constrained by host tolerance controls. This review discusses what is known about the immunological environment during HIV-1 infection, in particular alterations in CD4<sup>+</sup> Tfh, Treg, and Tfr populations and autoantibody generation, and how this is related to bnAb development, and considers the implications for HIV-1 vaccine design.

**Keywords:** autoantibody, broadly neutralizing antibody, CD4<sup>+</sup> T follicular helper cell, CD4<sup>+</sup> T follicular





## Supplementary Materials for

### **Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization**

Ivelin S. Georgiev, Nicole A. Doria-Rose, Tongqing Zhou, Young Do Kwon, Ryan P. Staupe, Stephanie Moquin, Gwo-Yu Chuang, Mark K. Louder, Stephen D. Schmidt, Han R. Altae-Tran, Robert T. Bailer, Krisha McKee, Martha Nason, Sijy O'Dell, Gilad Ofek, Marie Pancera, Sanjay Srivatsan, Lawrence Shapiro, Mark Connors, Stephen A. Migueles, Lynn Morris, Yoshiaki Nishimura, Malcolm A. Martin, John R. Mascola,\* Peter D. Kwong\*

\*Corresponding author. E-mail: jmascola@nih.gov (J.R.M.); pdkwong@nih.gov (P.D.K.)

Published 10 May 2013, *Science* **340**, 751 (2013)  
DOI: 10.1126/science.1233989

#### **This PDF file includes**

Materials and Methods  
Supplementary Text  
Figs. S1 to S15  
Tables S1 to S10  
Appendices S1 and S2  
Full References

ORIGINAL ARTICLE

## Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells

Malika Hale, Taylor Mesojednik, Guillermo S. Romano Ibarra, Jaya Sahni, Alison Bernard, Karen Sommer, Andrew M. Scharenberg, David J. Rawlings, Thor A. Wagner

DOI: <http://dx.doi.org/10.1016/j.ymthe.2016.12.023> | CrossMark

Article Info

Altmetric 7

Switch to Standard View



- PDF (1 MB)
- Extended PDF (1 MB)
- Download Images(.ppt)
- Email Article
- Add to My Reading List
- Export Citation
- Create Citation Alert
- Cited by in Scopus (0)

Summary Full Text Methods Images/Data References Related Articles

Expand all Collapse all

Hide Pane

The treatment or cure of HIV infection by cell and gene therapy has been a goal for decades. Recent advances in both gene editing and chimeric antigen receptor (CAR) technology have created new therapeutic possibilities for a variety of diseases. Broadly neutralizing monoclonal antibodies (bNAbs) with specificity for the HIV envelope glycoprotein provide a promising means of targeting HIV-infected cells. Here we show that primary human T cells engineered to express anti-HIV CARs based on bNAbs (HIVCAR) show specific activation and killing of HIV-infected versus uninfected cells in the absence of HIV replication. We also show that homology-directed recombination of the HIVCAR gene expression cassette into the *CCR5* locus enhances suppression of replicating virus compared with HIVCAR expression alone. This work demonstrates that HIV immunotherapy utilizing potent bNAb-based single-chain variable fragments fused to second-generation CAR signaling domains, delivered directly into the *CCR5* locus of T cells by homology-directed gene editing, is feasible and effective. This strategy has the potential to target HIV-infected cells in HIV-infected individuals, which might help in the effort to cure HIV.

